
收稿日期: 2025-09-28
录用日期: 2025-11-11
网络出版日期: 2026-04-28
基金资助
上海市加强公共卫生体系建设三年行动计划(2023—2025年)重点学科项目(GWVI-11.1-19);国家自然科学基金(81970574);国家自然科学基金(82170685);国家自然科学基金(82370743)
Association between hyperuricemia and metabolic syndrome in adults
Received date: 2025-09-28
Accepted date: 2025-11-11
Online published: 2026-04-28
Supported by
Key Disciplines Project of Shanghai Three-year Action Plan for Strengthening Public Health System Construction (2023?2025)(GWVI-11.1-19);National Natural Science Foundation of China(81970574)
目的·分析浙江省宁波市杭州湾地区成年人群高尿酸血症(hyperuricemia,HUA)的患病率,并探讨其与代谢综合征(metabolic syndrome,MS)及MS组分的相关性。方法·采用横断面研究设计,纳入2022年1月至12月于宁波市杭州湾医院进行健康体检的成年人作为研究对象。收集人口学资料及临床检查结果。根据血清尿酸(serum uric acid,SUA)水平计算该人群的HUA患病率;采用慢性肾脏病流行病学协作组公式计算估算肾小球滤过率(estimated glomerular filtration rate,eGFR);根据体质量指数(body mass index,BMI)、血压、空腹血糖、甘油三酯(triglyceride,TG)、高密度脂蛋白胆固醇(high-density lipoprotein cholesterol,HDL-C)判断是否患有MS。分析HUA与MS及其各组分之间的关联。结果·研究共纳入9 196名成年人,平均年龄为(34.3±11.8)岁,男性占75.2%,平均SUA为(371.8±95.6)μmol/L,HUA患病率为31.3%。HUA组较非HUA组男性比例更高、年龄更小、eGFR更低、MS患病率更高(均P<0.001),且MS各组分中BMI、血压、TG水平均更高,HDL-C水平更低(均P<0.001)。MS患者的SUA水平及HUA患病率均显著高于非MS患者(均P<0.001),且随着患者伴随的MS组分数目增加,SUA水平及HUA患病率逐渐升高。多因素Logistic回归分析结果显示,男性(OR=3.74,95%CI 3.12~4.48)、年轻(年龄每减少5岁,OR=1.22,95%CI 1.19~1.26)、eGFR<90 mL/(min·1.73 m2)(OR=2.45,95%CI 2.11~2.84)、BMI≥25 kg/m2(OR=2.31,95%CI 2.06~2.60)、血压偏高(OR=1.18,95%CI 1.04~1.32)、TG≥1.7 mmol/L(OR=2.08,95%CI 1.81~2.37)及低HDL-C(OR=1.33,95%CI 1.15~1.55)是HUA的独立危险因素。结论·宁波杭州湾地区成年人群中,HUA患病率较高;男性、年轻、肾功能下降、合并MS组分是该人群HUA患病的危险因素,且合并MS组分越多,患病率越高。
陆博涵 , 胡翠容 , 王瑾堃 , 陆继芳 , 金海姣 , 王玲 , 姜娜 , 牟姗 . 成人高尿酸血症与代谢综合征的关联研究[J]. 上海交通大学学报(医学版), 2026 , 46(4) : 486 -495 . DOI: 10.3969/j.issn.1674-8115.2026.04.008
Objective ·To analyze the prevalence of hyperuricemia (HUA) and its correlation with metabolic syndrome (MS) and MS components among adults in the Ningbo Hangzhou Bay area of Zhejiang Province. Methods ·A cross-sectional study was conducted among adults who underwent health examinations at Ningbo Hangzhou Bay Hospital from January to December 2022. Demographic data and clinical examination results were collected. The prevalence of HUA was calculated based on serum uric acid (SUA) levels. The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. MS was defined according to body mass index (BMI), blood pressure, fasting blood glucose, triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C). The association between HUA and MS, as well as its individual components, was analyzed. Results ·A total of 9 196 adults were included, with a mean age of (34.3±11.8) years; 75.2% were males. The mean SUA level was (371.8±95.6) μmol/L, and the overall prevalence of HUA was 31.3%. Compared with the non-HUA group, the HUA group demonstrated a higher proportion of males, younger age, lower eGFR, and a higher prevalence of MS (all P<0.001). Regarding MS components, the HUA group showed significantly higher BMI, blood pressure, and TG levels, along with lower HDL-C levels (all P<0.001). Patients with MS had significantly higher SUA levels and a higher prevalence of HUA compared to those without MS (both P<0.001). Furthermore, both SUA levels and the prevalence of HUA increased progressively with the increasing number of MS components present. Multivariable Logistic regression analysis identified male sex (OR=3.74, 95%CI 3.12‒4.48), younger age (per 5-year decrease, OR=1.22, 95%CI 1.19‒1.26), eGFR<90 mL/(min·1.73 m2) (OR=2.45, 95%CI 2.11‒2.84), BMI≥25 kg/m2 (OR=2.31, 95%CI 2.06‒2.60), elevated blood pressure (OR=1.18, 95%CI 1.04‒1.32), TG≥1.7 mmol/L (OR=2.08, 95%CI 1.81‒2.37), and low HDL-C (OR=1.33, 95%CI 1.15‒1.55) as independent risk factors for HUA. Conclusion ·The prevalence of HUA is high among the adult population in the Ningbo Hangzhou Bay area. Male sex, younger age, decreased renal function, and the presence of MS components are risk factors for HUA in this population, with the prevalence increasing as the number of MS components accumulates.
Key words: hyperuricemia (HUA); metabolic syndrome (MS); obesity; hypertension; dyslipidemia
| [1] | Major T J, Dalbeth N, Stahl E A, et al. An update on the genetics of hyperuricaemia and gout[J]. Nat Rev Rheumatol, 2018, 14(6): 341-353. |
| [2] | Kuwabara M, Kuwabara R, Niwa K, et al. Different risk for hypertension, diabetes, dyslipidemia, and hyperuricemia according to level of body mass index in Japanese and American subjects[J]. Nutrients, 2018, 10(8): 1011. |
| [3] | Johnson R J, Bakris G L, Borghi C, et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation[J]. Am J Kidney Dis, 2018, 71(6): 851-865. |
| [4] | Yanai H, Adachi H, Hakoshima M, et al. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease[J]. Int J Mol Sci, 2021, 22(17): 9221. |
| [5] | Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors[J]. Nat Rev Rheumatol, 2020, 16(7): 380-390. |
| [6] | Borghi C, Agabiti-Rosei E, Johnson R J, et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease[J]. Eur J Intern Med, 2020, 80: 1-11. |
| [7] | Chen-Xu M, Yokose C, Rai S K, et al. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007?2016[J]. Arthritis Rheumatol, 2019, 71(6): 991-999. |
| [8] | Koto R, Nakajima A, Horiuchi H, et al. Real-world treatment of gout and asymptomatic hyperuricemia: a cross-sectional study of Japanese health insurance claims data[J]. Mod Rheumatol, 2021, 31(1): 261-269. |
| [9] | Kim Y, Kang J H, Kim G T. Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample[J]. Clin Rheumatol, 2018, 37(9): 2529-2538. |
| [10] | Lohsoonthorn V, Dhanamun B, Williams M A. Prevalence of hyperuricemia and its relationship with metabolic syndrome in Thai adults receiving annual health exams[J]. Arch Med Res, 2006, 37(7): 883-889. |
| [11] | Singh S K, Singh R, Singh S K, et al. Prevalence of hyperuricemia and the relationship between serum uric acid and hypertension in new onset diabetic patients: a cross-sectional Indian study[J]. Diabetes Metab Syndr Obes, 2022, 15: 1809-1817. |
| [12] | Zhang M, Zhu X X, Wu J, et al. Prevalence of hyperuricemia among Chinese adults: findings from two nationally representative cross-sectional surveys in 2015?16 and 2018?19[J]. Front Immunol, 2021, 12: 791983. |
| [13] | Valsaraj R, Singh A K, Gangopadhyay K K, et al. Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement[J]. Diabetes Metab Syndr, 2020, 14(2): 93-100. |
| [14] | Alberti K G M M, Zimmet P, Shaw J. Metabolic syndrome: a new world-wide definition. A consensus statement from the International Diabetes Federation[J]. Diabet Med, 2006, 23(5): 469-480. |
| [15] | Fu Y Q, Yang H, Zheng J S, et al. Positive association between metabolic syndrome and serum uric acid in Wuhan[J]. Asia Pac J Clin Nutr, 2017, 26(2): 343-350. |
| [16] | Bowden R G, Richardson K A, Richardson L T. Uric acid and metabolic syndrome: findings from national health and nutrition examination survey[J]. Front Med, 2022, 9: 1039230. |
| [17] | Villegas R, Xiang Y B, Elasy T, et al. Purine-rich foods, protein intake, and the prevalence of hyperuricemia: the Shanghai Men's Health Study[J]. Nutr Metab Cardiovasc Dis, 2012, 22(5): 409-416. |
| [18] | Song P G, Wang H, Xia W, et al. Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China[J]. Sci Rep, 2018, 8(1): 4314. |
| [19] | Bray G A. Energy and fructose from beverages sweetened with sugar or high-fructose corn syrup pose a health risk for some people[J]. Adv Nutr, 2013, 4(2): 220-225. |
| [20] | Liu D M, Jiang L D, Gan L, et al. Association between serum uric acid level and body mass index in sex- and age-specific groups in southwestern China[J]. Endocr Pract, 2019, 25(5): 438-445. |
| [21] | He H J, Guo P, He J S, et al. Prevalence of hyperuricemia and the population attributable fraction of modifiable risk factors: evidence from a general population cohort in China[J]. Front Public Health, 2022, 10: 936717. |
| [22] | Li G Y, Qian X D, Ma C M, et al. The dose-response relationship between sex hormones and hyperuricemia in different gender: NHANES 2013?2016[J]. Front Endocrinol, 2022, 13: 1035114. |
| [23] | Ioannou G N, Boyko E J. Effects of menopause and hormone replacement therapy on the associations of hyperuricemia with mortality[J]. Atherosclerosis, 2013, 226(1): 220-227. |
| [24] | Kielstein J T, Pontremoli R, Burnier M. Management of hyperuricemia in patients with chronic kidney disease: a focus on renal protection[J]. Curr Hypertens Rep, 2020, 22(12): 102. |
| [25] | Su H Y, Yang C, Liang D, et al. Research advances in the mechanisms of hyperuricemia-induced renal injury[J]. Biomed Res Int, 2020, 2020: 5817348. |
| [26] | Li C H, Lee C L, Hsieh Y C, et al. Hyperuricemia and diabetes mellitus when occurred together have higher risks than alone on all-cause mortality and end-stage renal disease in patients with chronic kidney disease[J]. BMC Nephrol, 2022, 23(1): 157. |
| [27] | Chen W Y, Fu Y P, Zhou M. The bidirectional relationship between metabolic syndrome and hyperuricemia in China: a longitudinal study from CHARLS[J]. Endocrine, 2022, 76(1): 62-69. |
| [28] | 刘静红. 农村老年人群高尿酸血症与代谢综合征相互影响的双向关联队列研究[D]. 苏州: 苏州大学, 2021. |
| Liu J H. A cohort study on the bidirectional associations between hyperuricemia and metabolic syndrome among rural older adults[D]. Suzhou: Soochow University, 2021. | |
| [29] | Li C G, Hsieh M C, Chang S J. Metabolic syndrome, diabetes, and hyperuricemia[J]. Curr Opin Rheumatol, 2013, 25(2): 210-216. |
| [30] | You L L, Liu A P, Wuyun G W, et al. Prevalence of hyperuricemia and the relationship between serum uric acid and metabolic syndrome in the Asian Mongolian area[J]. J Atheroscler Thromb, 2014, 21(4): 355-365. |
| [31] | Yuan H P, Yu C L, Li X H, et al. Serum uric acid levels and risk of metabolic syndrome: a dose-response meta-analysis of prospective studies[J]. J Clin Endocrinol Metab, 2015, 100(11): 4198-4207. |
| [32] | Kanbay M, Jensen T, Solak Y, et al. Uric acid in metabolic syndrome: from an innocent bystander to a central player[J]. Eur J Intern Med, 2016, 29: 3-8. |
| [33] | Zhang Y, Tan M, Liu B Y, et al. Relationship between bone mineral density and hyperuricemia in obesity: a cross-sectional study[J]. Front Endocrinol, 2023, 14: 1108475. |
| [34] | Zhang Y, Zhang M M, Yu X W, et al. Association of hypertension and hypertriglyceridemia on incident hyperuricemia: an 8-year prospective cohort study[J]. J Transl Med, 2020, 18(1): 409. |
| [35] | Liu X Y, Wu Q Y, Chen Z H, et al. Elevated triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio increased risk of hyperuricemia: a 4-year cohort study in China[J]. Endocrine, 2020, 68(1): 71-80. |
| [36] | Lee T S, Lu T M, Chen C H, et al. Hyperuricemia induces endothelial dysfunction and accelerates atherosclerosis by disturbing the asymmetric dimethylarginine/dimethylarginine dimethylaminotransferase 2 pathway[J]. Redox Biol, 2021, 46: 102108. |
/
| 〈 |
|
〉 |